Lineage Cell Therapeutics, Inc. (LCTX) Net margin 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) net profit margin by fiscal year — reported net income divided by reported revenue.
-436.5%FY2025 · since FY2016: 566.8% → -436.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -436.5% | -240.6 pp |
| FY2024 | -195.9% | +44.3 pp |
| FY2023 | -240.2% | -61.5 pp |
| FY2022 | -178.7% | +812.3 pp |
| FY2021 | -991.0% | +139.8 pp |
| FY2020 | -1130.8% | -797.7 pp |
| FY2019 | -333.1% | +588.9 pp |
| FY2018 | -922.0% | -344.3 pp |
| FY2017 | -577.7% | -1144.5 pp |
| FY2016 | 566.8% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →